THRomboprophylaxis in Individuals undergoing superficial endoVEnouos treatment (THRIVE): a multicentre assessor-blind randomized controlled trial

Imperial College London0 个研究点目标入组 6,660 人开始时间: 2023年9月15日最近更新: 2024年3月4日

试验速览

2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38367965/ (added 19/02/2024)

•1. Adults (>18 years)
•2. Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia
•3. Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue

•Current exclusion criteria as of 12/01/2024:
•1. Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation
•2. Previous personal or first-degree relative history of VTE
•3. Thrombophilia
•4. Female patients of childbearing potential who have a positive pregnancy test
•5. A history of allergy to heparins or direct oral anticoagulants
•6. A history of heparin-induced thrombocytopenia
•7. Inherited and acquired bleeding disorders
•8. Evidence of active bleeding
•9. Concomitant major health problems such as active cancer and chronic renal and/or liver impairment
•10. Known thrombocytopenia (platelets known to be less than 50 x 109/l)
•11. Surgery or major trauma in the previous 90 days
•12. Recent ischemic stroke in the previous 90 days
•13. Inability to provide consent
•Previous exclusion criteria:
•1. Clinical indication for therapeutic anticoagulation
•2. Clinical contraindication to anticoagulation
•3. Previous personal or family history of VTE
•4. Thrombophilia
•5. Inability to provide informed consent or consent by personal/professional legal representative
•6. A positive test for SARS-CoV2 <3 months of procedure
•7. Female patients of childbearing age who have a positive pregnancy test

发起方